- Case Report
- Open Access
Dose-dependence of protection from systemic reactions to venom immunotherapy by omalizumab
Clinical and Molecular Allergy volume 14, Article number: 14 (2016)
Systemic reactions (SR) to venom immunotherapy (VIT) are rare but may occur, with a rate significantly higher for honeybee than for vespid VIT. In patients with repeated SRs to VIT it is difficult to reach the maintenance dose of venom and pre-treatment with omalizumab is indicated, as shown by some studies reporting its preventative capacity, when antihistamines and corticosteroids are ineffective.
We present the case of a 47 years old woman allergic to bee venom who experienced two severe SRs after bee stings and several SRs to VIT with bee venom. Pre-treatment with antihistamines and corticosteroids as well as omalizumab at doses up to 300 mg was unsuccessful, while an omalizumab dose of 450 mg finally achieved in our patient the protection from SRs to VIT with 200 mcg of bee venom.
The search of the dose of omalizumab able to protect a patient with repeated SRs to VIT may be demanding, but this search is warranted by the need to provide to this kind of patient, by an adequate VIT, the protection from potentially life-threatening reactions.
Venom immunotherapy (VIT) is generally safe and, differently from injective immunotherapy with inhalant allergens, no fatal reaction to treatment has been reported . Still, systemic reactions (SR) may occur, with a rate significantly higher for honeybee than for vespid VIT. In fact, a systematic review defined a rate of SRs of 25.1 % for honeybee VIT and 5.8 % for vespid VIT . In patients with repeated SRs it is difficult to reach the maintenance dose of venom, usually corresponding to 100 mcg . Mild to moderate SRs may be averted by pre-treatment with antihistamines , while for severe SRs pre-treatment with omalizumab is indicated, as shown by some studies reporting its preventative capacity [4–6]. However, a negative study was published . We describe the case of a patient with repeated SRs to honeybee VIT who initially was apparently not responsive to the omalizumab treatment but achieved the complete prevention of SRs by dose increase.
The patient is a woman exposed to honeybee stings because her father is a beekeeper. At the age of 22 years she experienced a SR of grade 4 severity according to Mueller  after a single bee sting. Honeybee venom hypersensitivity was then diagnosed by skin tests and VIT for bee venom was started. However, the treatment was withdrawn early, due to repeated SRs to VIT. No other stings until the age of 47 years when the patient had a further SR (again grade 4 according to Mueller) after a bee sting. Patient’s clinical features are reported in Table 1. According to clinical history, no additional allergy neither other medical conditions were present. In 2013, VIT for bee venom was then scheduled by honeybee venom from Stallergenes (Antony, France) but already during the build-up phase, at the dose of 10 mcg of venom, a SR with angioedema of the glottis, cough, itching of hands and feet occurred, requiring epinephrine administration for resolution of the symptoms (Table 2). Premedication with terfenadine 180 mg twice a day in the three days before VIT was attempted but anaphylaxis occurred again at the dose of 10 mcg and administration of epinephrine was again necessary. Therefore, VIT for bee was once more planned using premedication with terfenadine and anti-IgE for preventing SRs. Omalizumab 300 mg was administered twice with a 14 day interval during the build-up phase of VIT with a modified rush schedule at weekly interval (Table 3). However, when reaching the dose of 10 mcg the patient had cough and dysphagia. Changing the premedication to omalizumab plus intravenous hydrocortisone 500 mg, intravenous ranitidine 50 mg and cetirizine 10 mg/os, a maintenance dose of 200 mcg of bee venom was reached in 11 weeks and well tolerated in the following months. This suggested to step down omalizumab to 150 mg every 2 weeks and using oral premedication with prednisone 25 mg, rupatadine 10 mg and ranitidine 150 mg. VIT and omalizumab administrations were set on different days. However, when omalizumab was reduced to 150 mg once a month a SR requiring epinephrine occurred. Therefore, the dose of omalizumab was doubled to 300 mg once a month along with the oral premedication with the usual drugs letting the patient tolerating the monthly dose of 200 mcg of bee venom. However, seven months later, the same premedication regimen was not able to prevent a new SR to VIT. Finally, when increasing the dose of omalizumab to 450 mg monthly, 2 days before VIT, preceded by oral premedication with prednisone, rupatadine and ranitidine 12 and 2 h before VIT, the patient no longer suffered from SRs over the last 14 months and is still under regular treatment.
VIT is a highly effective treatment but not all patients are protected from SRs by the usual maintenance dose of 100 mcg. Rueff et al. demonstrated that in all patients not completely protected from stings a protective dose may be individuated, that in rare cases may be as high as 400 mcg .
The case we report shows that also the search of the dose of omalizumab able to protect a patient with repeated SRs to VIT may be demanding, but this pursuit is warranted by the need to provide to this kind of patient, by an adequate VIT, the protection from potentially life-threatening reactions. In previous reports, the minimal effective dose of omalizumab to protect from systemic reactions to VIT was 150 mg , thus the search of the protective dose should start from 150 mg, with increase to 300 mg and, possibly, to 450 mg in case of incomplete protection. The most appropriate combination therapy including also corticosteroids and antihistamines is not yet established and needs be investigated.
Boyle RJ, Elremeli M, Hockenhull J, Cherry MG, Bulsara MK, Daniels M, Oude Elberink JN. Venom immunotherapy for preventing allergic reaction to insect stings. Cochrane Database Syst Rev 2012: CD008838.
Incorvaia C, Frati F, Dell’Albani I, Robino A, Cattaneo E, Mauro M. Safety of hymenoptera venom immunotherapy: a systematic review. Expert Opin Pharmacother. 2011;12(16):2527–32.
Gorska L, Chelminsha M, Kuziemski K, Skrzypski M, Niedoszytko M, Damps-Konstanska I, et al. Analysis of safety, risk factors and pretreatment methods during rush hymenoptera venom immunotherapy. Int Arch Allergy Immunol. 2008;147(3):241–5.
Wieczorek D, Kapp A, Wedi B. Intolerance of specific immunotherapy with Hymenoptera venom: jumping the hurdle with omalizumab. Hautarzt. 2014;65(9):791–5.
Galera C, Soohun N, Zankar N, Caimmi S, Gallen C, Demoly P. Severe anaphylaxis to bee venom immunotherapy: efficacy of pre-treatment and concurrent treatment with omalizumab. J Investig Allergol Clin Immunol. 2009;19(3):225–9.
Kontou-Fili K. High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis. Allergy. 2008;63(3):378.
Soriano Gomis V, Gonzalez Delgado P, Niveiro Hernandez E. Failure of omalizumab treatment after recurrent systemic reactions to bee-venom immunotherapy. J Investig Allergol Clin Immunol. 2008;18(3):225–6.
Mueller HL. Diagnosis and treatment of insect sensitivity. J Asthma Res. 1966;3:331–3.
Rueff F, Wenderoth A, Przybilla B. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol. 2001;108:1027–32.
Palgan K, Bartuzi Z, Gotz-Zbikowska M. Treatment with a combination of omalizumab and specific immunotherapy for severe anaphylaxis after a wasp sting. Int J Immunopathol Pharmacol. 2014;27:109–12.
All authors contributed in collection of data and in the writing of the manuscript.
E.B. has received a grant from Allergy Therapeutics for a scientific consultancy; C.I. is a scientific consultant for Stallergenes Italy; M.M. has received a grant from ALK for the project “ALK Venom Expert”.
Consent for publication
Signed consent to publish was obtained from the patient.
About this article
Cite this article
Boni, E., Incorvaia, C. & Mauro, M. Dose-dependence of protection from systemic reactions to venom immunotherapy by omalizumab. Clin Mol Allergy 14, 14 (2016). https://doi.org/10.1186/s12948-016-0051-2
- Venom immunotherapy
- Systemic reactions